Tests sacituzumab govitecan and nivolumab after bladder cancer surgery
Tests two drugs after surgery in adults with bladder cancer at high risk of return.
Key facts
- Who runs it
- University of California, Irvine
- Where
- Orange, United StatesSee the site
- Trial code
- Registry title
- Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 23 people, planned
- Started
- 15 Nov 2024
- Expected to end
- 1 Dec 2026
- Type of study
- Interventional
- Treatments tested
- Sacituzumab Govitecan (SG)
- Nivolumab
- Record updated
- 30 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had surgery for muscle-invasive urothelial cancer and have a high risk that the cancer returns. They get sacituzumab govitecan with nivolumab after surgery.
- Age
- 18 years or older
- Sex
- Men and women can join.
- Disease stage
- Muscle-invasive urothelial cancer of the bladder, ureter or renal pelvis, removed by surgery (radical cystectomy or nephroureterectomy) within 180 days before treatment starts. No sign of disease on imaging within 28 days of the first treatment day. High risk of return: pathologic T2, T3, T4 or N+ disease after chemotherapy before surgery, or T3, T4 or N+ disease without it.
- Earlier treatment
- Platinum-based chemotherapy before surgery is allowed. People who had no chemotherapy must be unable to take cisplatin or refuse platinum chemotherapy after surgery. Earlier treatment with PD-1/PD-L1 inhibitors or sacituzumab govitecan, any treatment after surgery, or radiation for urothelial cancer rules a person out.
Main reasons for not taking part
- Partial cystectomy or partial nephrectomy
- Cancer spread to other organs seen on imaging
- Active or suspected autoimmune disease
- History of lung inflammation such as pneumonitis or pulmonary fibrosis
- Pregnancy or breastfeeding
The registry criteria, word for word
Show all 54 criteriaShow less
Who can take part
- Age ≥ 18 years at the time of study consent
- ECOG Performance Status of 0, 1 or 2 (see Appendix A)
- Histologically confirmed muscle-invasive UC originating in the bladder, ureter, or renal pelvis. Variant histology, except small cell carcinoma, is allowed
- Underwent curative-intent surgery (i.e. RC or nephroureterectomy), performed within 180 days prior to study treatment initiation
- Radiographic disease-free status as determined by imaging within 28 days of C1D1 of study treatment
- Prior platinum-based NAC is allowed. If chemotherapy-naive, patient must be Cisplatin-ineligible (based on Galsky et al 2011 [10]) or refuse platinum AC
- Prior treatment with neoadjuvant investigational agents is allowed (except PD-1/PD-L1 inhibitors or sacituzumab govitecan). No washout from neoadjuvant therapy is required
- If NAC was given, patient must be considered at high risk for cancer recurrence due to having pathologic T2, T3, T4, or N+ disease on RC or nephroureterectomy surgical spec-imen
- If no NAC was given, patient must be considered at high risk for cancer recurrence due to having pathologic T3, T4, or N+ disease on RC or nephroureterectomy surgical speci-men
- Adequate organ and marrow function as defined below:
- ANC ≥ 1000/mcL
- Platelets ≥ 100,000/mcL
- Total bilirubin ≤ 1.5 × institutional ULN (or ≤ 3.0 × ULN for subjects with Gilbert's disease)
- AST/ALT ≤ 3 × institutional ULN
- Alkaline phosphatase ≤ 3 × institutional ULN
- Serum albumin ≥ 2.8 g/dL
- Creatinine Creatinine clearance of ≥30 mL/min (calculated with Cockroft-Gault formula)
- Hemoglobin ≥ 9.0 g/dL
- aPTT ≤ 1.5 × institutional ULN
- Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception (i.e. barrier methods including male condom, female condom, or diaphragm with spermicidal gel, etc.) that are approved by the Investigator. Contra-ception must be used during the course of the treatment and for 6 months after the last dose of study treatment
- Female subjects of childbearing potential must not be pregnant following signing the study consent form. Female subjects are considered to be of childbearing potential unless one of the following criteria are met: documented permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal sta-tus (defined as at least 12 months of amenorrhea in a woman ≥ 45 years-of-age in the ab-sence of other biological or physiological causes)
- Recovery to ≤ Grade 1 of CTCAE version 5 toxicities related to any prior treatment for UC, unless the AE(s) is clinically non-significant and/or stable on supportive therapy as per discretion of the Investigator
- Subjects with any type of genitourinary catheters (i.e. nephrostomy, Foley, etc) are al-lowed
- Ability to understand and the willingness to sign a written informed consent. Both men and women and members of all races and ethnic groups are eligible for this trial. Non-English speaking, hard of hearing, and illiterate individuals are eligible for this trial
Who cannot take part
- History of adjuvant platinum-based chemotherapy or any other type of adjuvant therapy, including investigational agents, following surgical removal of UC
- History of treatment with PD-1/PD-L1 inhibitors or sacituzumab govitecan prior to study treatment initiation
- History of previous radiation therapy for treatment of UC
- Receipt of or planning to receive any other concurrent investigational agents
- Conditions requiring treatment with either systemic high-dose corticosteroids (e.g. prednisone dose of ≥ 10 mg or equivalent) or other immunosuppressive medications within 14 days of study treatment initiation
- Major surgery within 28 days or minor surgery within 14 days before the first dose of study treatment. Subjects must have complete wound healing and resolution from complications of major or minor surgery before first dose of study treatment
- Stroke (including transient ischemic attack (TIA), myocardial infarction (MI), or other ischemic arterial event within 90 days before first dose of study treatment
- Severe, uncontrolled bleeding within 14 days before first dose of study treatment
- Uncontrolled diarrheal illness ≥ Grade 3 in severity within 14 days before first dose of study treatment
- Received a live vaccine within 28 days prior to the first dose of study treatment
- History of active, known, or suspected autoimmune disease
- Inhaled or topical steroids are permitted in the absence of active autoimmune dis-ease
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
- Active malignancy within 3 years of study entry, except treated localized non-melanoma skin cancer, Gleason 6 prostate cancer on active surveillance, or curatively treated in situ cancer of the breast or cervix
- Uncontrolled intercurrent illness including, but not limited to, the following conditions:
- Active and/or uncontrolled bacterial, viral, or fungal infection within 7 days of study treatment initiation
- History of HIV infection with detectable viral load
- History of Hepatitis B or C infection with detectable viral load
- History of severe liver impairment (Child-Pugh C liver cirrhosis)
- History of active tuberculosis (Bacillus tuberculosis)
- Congestive heart failure New York Heart Association (NYHA) Class 3 or 4, unstable angina pectoris, or serious uncontrolled cardiac arrhythmias
- History of inflammatory bowel disease (i.e. ulcerative colitis, Crohn's disease, etc.) or any other condition that puts patients at high risk of developing severe diarrhea
- Psychiatric illness/social situations causing inability to comply with study proce-dures or follow up
- Known or suspected severe hypersensitivity (Grade ≥ 3) to nivolumab, sacituzumab govitecan, irinotecan, and/or any of their components
- History or current evidence of any condition, therapy, or laboratory/radiographic abnormal-ity that might confound the results of the study, interfere with the patient's ability to participate for the full duration of the study, or is not in the best interest of the patient to partici-pate in the study, in the opinion of the Investigator
- Underwent a partial cystectomy or partial nephrectomy
- Radiographic evidence of metastasis
- Patients who do not have adequate organ and marrow function, as defined in Section 4.1 above
- Pregnancy at the time of or following study consent
- Breastfeeding at the time of or following study consent
Where in United States
- Chao Family Comprehensive Cancer Center, University of California, IrvineOrange, United StatesContact: Nataliya Mar, MDTaking people
About the trial
What the trial wants to find out
This is a phase 2 study, single-arm study of adjuvant combination therapy with Sacituzumab Govitecan and Nivolumab in patients with muscle-invasive urothelial carcinoma of the bladder, ureter, or upper tract, who are high risk for cancer recurrence post curative-intent surgery based on surgical pathology.
The group in the trial
- Sacituzumab Govitecan PLUS NivolumabTreatment being tested
Patients eligible for this study treatment will receive combination therapy with Sacituzumab Govitecan with Nivolumab for 4 cycles, followed by single-agent Nivolumab for an additional 11 cycles.
Treatment: Sacituzumab Govitecan (SG) and Nivolumab
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Adjuvant Sacituzumab Govitecan Plus Nivolumab in Patients With Muscle-Invasive Urothelial Carcinoma at High-Risk for Recurrence
- Plain-language title
- Tests sacituzumab govitecan and nivolumab after bladder cancer surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 30 April 2026